Nycomed Amersham's Sonazoid
This article was originally published in The Gray Sheet
New drug application is submitted for the ultrasound contrast agent. Based on results with 1,300 patients in Europe and the U.S., the NDA includes clinical data "demonstrating echocardiographic improvement in endocardial border delineation and left ventricular opacification following administration" of the drug, the firm says Aug. 6. On Aug. 3, FDA approved Diatide's NDA for the lung cancer detection agent NeoTect, which Nycomed Amersham is co-promoting in the U.S. (1see related story, p. 10)
You may also be interested in...
Diatide says that a $2 mil. milestone payment from marketing partner Nycomed Amersham triggered by FDA's Aug. 3 approval of NeoTect will be used in part to bolster its own marketing efforts for the lung cancer imaging agent.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.